| Literature DB >> 32000429 |
Peiyi Li1, Zhanqi Duan2, Ziwu Zhang2, Yunzhen He3, Weimin Li4.
Abstract
To address the remaining medical misconducts after the zero-makeup drug policy (ZMDP), e.g., over-examinations, China has given the priority to government supervision on medical institutions. This study evaluated the effect of government supervision on medical costs among inpatients with chronic obstructive pulmonary disease (COPD) in Sichuan province, the first province in China where the medical supervision was conducted.A linear interrupted time series (ITS) model was employed to analyze data about 72,113 inpatients from 32 hospitals. Monthly average medicine costs, diagnostic costs, and medical services costs, nursing costs from January 2015 to June 2018 were analyzed, respectively.The average hospitalization costs fell with a monthly trend of 42.90Yuan before the implementation of supervision (P < .001), and the declining trend remained with the more dramatic rate (-158.70Yuan, P < .001) after the government audit carried out. For western medicine costs, the monthly decreasing trend remained after the implementation of supervision (-66.44Yuan, P < .001); meanwhile, the monthly upward trend was changed into a downtrend trend for traditional Chinese medicine costs (-11.80Yuan, P = .009). Additionally, the increasing monthly trend in average diagnostics costs disappeared after government supervision, and was inversed to an insignificant decreasing trend at the rate of 26.18Yuan per month. Moreover, the previous upward trends were changed into downward trends for both medical service costs and nursing costs (P = .056, -44.71Yuan; P = .007, -11.17Yuan, respectively) after the supervision carried out.Our findings reveal that government supervision in Sichuan province was applicable to curb the growth of medical costs for inpatients with COPD, which may reflect its role in restraining physicians' compensating behaviors after the ZMDP. The government medical supervision holds promise to dismiss medical misconducts in Sichuan province, the experience of which may offer implications for other regions of China as well as other low- and middle-income countries.Entities:
Mesh:
Year: 2020 PMID: 32000429 PMCID: PMC7004713 DOI: 10.1097/MD.0000000000018977
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Characteristics of 32 representative hospitals.
Figure 1Trend in the monthly average Total hospitalization costs for 32 hospitals in Sichuan.
Estimated coefficients of segmented regression model for the monthly average medical costs in 32 hospitals before and after supervision (RMB,Yuan).
Figure 2Trend in the monthly average TCM costs for 32 hospitals in Sichuan. TCM, Traditional Chinese medicine.
Figure 3Trend in the monthly average Diagnostic costs for 32 hospitals in Sichuan.